KINIKSA PHARMACEUTICALS LTD

NASDAQ: KNSA (Kiniksa Pharmaceuticals Interna)

Last update: 22 hours ago

92.24

-5.32 (-5.45%)

Previous Close 97.56
Volume 1,317,723
Price / Earnings (Forward) 73.39
Price / Sales 8.59
Price / Book 10.79
52 Weeks Range
36.56 (-60%) — 98.48 (6%)
Profit Margin -3.52%
Operating Margin (TTM) 9.63%
Diluted EPS (TTM) -0.240
Quarterly Revenue Growth (YOY) 72.50%
Total Debt/Equity (MRQ) 2.17%
Current Ratio (MRQ) 3.66
Operating Cash Flow (TTM) 44.03 M
Levered Free Cash Flow (TTM) 25.15 M
Return on Assets (TTM) -1.77%
Return on Equity (TTM) -3.81%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock Kiniksa Pharmaceuticals Interna Mixed Bearish

AIStockmoo Score

0.0
Analyst Consensus 0.0
Insider Activity NA
Price Volatility -3.0
Technical Moving Averages 0.0
Technical Oscillators 2.0
Relative Valuation NA
Financial Health 2.0
Macro Environment -0.3
AI Insight NA
AI Technical NA
Weighted Average -0.05

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
KNSA - - - 10.79
LQDA 4 B - 31.25 30.96
ETON - - - 31.66
HROW - - - 69.57
BCRX - - - -
GELS - - - 0.560

Select this tab to load the latest available analysis.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Growth
% Held by Insiders 3.80%
% Held by Institutions 97.31%

No data within this time range.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria